Reglan® Lawyers For Tardive Dyskinesia Injury Victims
Reglan® (metoclopramide) was FDA-approved in the early 1980s for short-term treatment (between 4 and 12 weeks) of common gastrointestinal disorders such as gastroesophageal reflux disease (GERD), persistent heartburn, nausea, vomiting, and a feeling of stomach fullness. Reglan and other generic forms of Reglan known as metoclopramide have been linked to a disabling neurological syndrome called Tardive Dyskinesia when these medications are used longer than 12 weeks. Tardive Dyskinesia, which is often irreversible and may become permanent, is characterized by involuntary movements of the face, including grimacing, lip movement and puckering, sticking out the tongue, tongue rolling and teeth grinding. In some cases, Tardive Dyskinesia may cause uncontrollable movements of the arms and legs. Tardive Dyskinesia can mimic disorders such as Parkinson's disease, Tourette's syndrome, Huntington's chorea, tics, cerebral palsy, stroke, and hyperactivity.
In June 2009, the manufacturers of Reglan and metoclopramide were required to update their product labels to warn of the increased likelihood of suffering Tardive Dyskinesia by including such a warning in the “Black Box” section of the label, which is the strongest warning level issued by the FDA.
Thousands of lawsuits have been filed in numerous courts across the country against the manufacturers of Reglan, alleging that the defendants did not warn consumers or physicians of the risks associated with long term use of Reglan/metoclopramide. Neither patients nor physicians were aware of the risk of developing Tardive Dyskinesia when Reglan/metoclopramide is used long-term, and therefore, many patients took Reglan/metoclopramide for an extended period of time and subsequently developed Tardive Dyskinesia.
Schlichter Bogard & Denton is no longer accepting Reglan/metoclopramide cases and therefore, the information on this page is provided for informational purposes.